Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol in Symptomatic Cavernous Malformation
NCT03474614Phase 2Terminated
- Sponsor
- St. Joseph's Hospital and Medical Center
- Start
- Jan 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of propranolol in cerebral cavernous malformation (CCM) (2 arms), sponsored by St. Joseph's Hospital and Medical Center. Primary endpoint: Global messenger RNA (mRNA) and microRNA (miRNA) expression. Started Jan 2018; status: terminated.
02
Drugs
propranolol
03
Conditions
cerebral cavernous malformation (CCM)
Beyond the preview
Go deeper on NCT03474614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474614.